Breakthrough HIV Prevention ⁢Drug Faces Hurdles Despite WHO Guidance

New WHO recommendations ‍simplify HIV testing for PrEP users,‍ but a landmark deal ⁣for the long-acting injectable lenacapavir is drawing scrutiny over its limited reach and opaque ⁤pricing.

Simplified Testing Boosts PrEP Accessibility

The World Health organization (WHO) has issued updated guidance⁢ simplifying HIV ⁢testing requirements for‍ individuals using pre-exposure prophylaxis (PrEP). Crucially, the recommendations confirm that readily available rapid HIV tests are suitable for people taking all forms of PrEP,⁢ including the newer long-acting injectables.⁢ This move eliminates the need for expensive and, as it turns out, unreliable RNA (viral load) tests, which were initially hoped to⁤ detect⁢ breakthrough infections more rapidly.The ⁣simplification is expected to streamline PrEP‍ delivery and improve user experience.

Lenacapavir Deal: Ambitious Goals or Limited Impact?

While the WHO guidance has been widely praised, a important deal between the Global Fund and Gilead for the groundbreaking injectable PrEP ⁤drug, lenacapavir, has sparked debate. Under this arrangement, the Global Fund will purchase lenacapavir for up to two million people in 120 low- and middle-income⁣ countries. Though, many public health advocates argue that this target is insufficient to meet the vast need for effective HIV prevention.

Adding to the concerns, countries wishing ‍to provide lenacapavir to ⁣their populations must contribute a portion of ‍the cost from their⁤ existing Global Fund allocations. These grants are already strained due to reduced US contributions, leading to cuts of 10% or more ⁢for many nations. This financial pressure means that essential programs were ⁢already facing scaling back or restructuring, even before the added demand of supporting lenacapavir access.

Price Secrecy and Cost Concerns

the confidentiality surrounding the price paid by the Global Fund to Gilead for lenacapavir has also drawn criticism. Professor Beatriz⁢ Grinsztejn, president of the International AIDS Society, expressed her disappointment at the opening ceremony of a recent conference, stating that the lack ‍of transparency diminishes the negotiating power of countries outside the Global Fund, particularly middle-income nations grappling with persistently high HIV incidence rates.While officially confidential, figures discussed at the conference suggest the Global Fund is paying approximately ⁢US$100 per person per year for lenacapavir. Of this, countries are ⁣expected to allocate $60 ‍from their existing grants, with the⁤ remaining $40 provided by the Children’s Investment Fund⁣ Foundation.these costs are notably ⁣higher than those for other PrEP options. Cabotegravir, another ‍long-acting injectable PrEP supplied by ViiV, reportedly costs around $160 per person, while oral PrEP from generic manufacturers is available for between $25 and $40.

The Path to Generic Access and Market Shaping

The current pricing and ‍funding model raises ⁤concerns that lenacapavir may remain a niche product, accessible only to a limited ⁣number of⁤ countries and a⁣ subset of at-risk populations. carolyn Amole of CHAI highlighted that only a select few ⁤countries can initiate the drug’s rollout under these conditions, especially given the current fiscal constraints.

Amole’s hopes are pinned on the subsequent stage: the ⁤introduction of generic lenacapavir, ideally from multiple manufacturers. She stressed the critical need for a ‍carefully managed market-shaping strategy that influences both supply and demand. “Working ‍only in one area without the other will fail every ⁢time,” she stated.⁣ “You cannot negotiate ⁢a pricing deal without knowing whether the volumes will be there, and it is indeed risky to drive demand for⁣ a product without knowing if you will actually have a product.”

If such a strategy is effectively implemented, Amole believes it could pave ⁣the way for generic lenacapavir to become available as early as the first quarter of 2027, at a price competitive with ⁤existing oral PrEP options. This would substantially expand access to this vital long-acting prevention method for millions more worldwide.